Barclays reiterated an Overweight rating and $209 price target on Sarepta (SRPT) after the company reported a patient death post treatment of Elevidys due to acute liver failure. While one patient death was somewhat surprising and unfortunate, the liver toxicity was known, and the cause could be a multi-factor, particularly patient condition, the analyst tells investors in a research note. The firm added that initial feedback suggested limited impact on Elevidys patient use, and believes the stock reaction is overdone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta update could boost enrollment in Regenxbio study, says Morgan Stanley
- Sarepta news opens door for Regenxbio over risk/benefit profile, says Leerink
- Analysts remain optimistic about Elevidys after Sarepta reports patient death
- Buy Rating Maintained for Sarepta Therapeutics Despite Safety Concerns with Elevidys
- Leerink says Sarepta stock reaction ‘overdone,’ remains positive on Elevidys